An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher
- 1 November 2021
- journal article
- editorial
- Published by American Public Health Association in American Journal of Public Health
- Vol. 111 (11), 1923-1926
- https://doi.org/10.2105/ajph.2021.306495
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017JAMA Network Open, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsThe New England Journal of Medicine, 2019
- Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against SmallpoxThe New England Journal of Medicine, 2019
- The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpoxAntiviral Research, 2019
- Oral Tecovirimat for the Treatment of SmallpoxThe New England Journal of Medicine, 2018
- Experience With the Priority Review Voucher Program for Drug DevelopmentJAMA, 2015
- Opioid Abuse in the United States and Department of Health and Human Services Actions to Address Opioid-Drug-Related Overdoses and DeathsJournal of Pain & Palliative Care Pharmacotherapy, 2015
- Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice.2007
- Smallpox vaccination and bioterrorism with pox virusesComparative Immunology, Microbiology and Infectious Diseases, 2003